{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:12:59Z","timestamp":1791893579064,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.semnephrol.2023.151478","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T10:07:26Z","timestamp":1705572446000},"page":"151478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bleeding Risk in Hemodialysis Patients"],"prefix":"10.1016","volume":"43","author":[{"given":"Anita","family":"van Eck van der Sluijs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbey","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7624","article-title":"Trends in mortality due to myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis","volume":"5","author":"Ocak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151476","article-title":"How to ensure patency of the extracorporeal circuit in hemodialysis: global perspectives","author":"Santos","year":"2023","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151477","article-title":"Laboratory monitoring of heparin anticoagulation Q1 in hemodialysis: rationale and strategies","author":"Chiasakul","year":"2023","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2215\/CJN.01810407","article-title":"Major bleeding in hemodialysis patients","volume":"3","author":"Holden","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151478_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1681\/ASN.2011070658","article-title":"Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients","volume":"23","author":"Yang","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151478_bib0006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ki.2013.170","article-title":"Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: Results from the DOPPS","volume":"84","author":"Sood","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0895-4356(01)00461-9","article-title":"Incidence of serious upper gastrointestinal bleeding\/perforation in the general population: Review of epidemiologic studies","volume":"55","author":"Hern\u00e1ndez-D\u0131\u0301az","year":"2002","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/00365521.2012.763174","article-title":"Upper gastrointestinal bleeding: Incidence, etiology and outcomes in a population-based setting","volume":"48","author":"Hreinsson","year":"2013","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151478_bib0009","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1572-0241.2003.07517.x","article-title":"Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993\/1994 and 2000","volume":"98","author":"van Leerdam","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10620-013-2973-6","article-title":"Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis","volume":"59","author":"Huang","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"36","key":"10.1016\/j.semnephrol.2023.151478_bib0011","doi-asserted-by":"crossref","first-page":"e1482","DOI":"10.1097\/MD.0000000000001482","article-title":"Different risk of common gastrointestinal disease between groups undergoing hemodialysis or peritoneal dialysis or with non-end stage renal disease: A nationwide population-based cohort study","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151478_bib0012","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.08140814","article-title":"Comparison of subdural hematoma risk between hemodialysis and peritoneal dialysis patients with ESRD","volume":"10","author":"Wang","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0013","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ndt\/gfaa216","article-title":"Bleeding risk of haemodialysis and peritoneal dialysis patients","volume":"36","author":"van Eck van der Sluijs","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151478_bib0014","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1097\/01.ASN.0000145014.80714.35","article-title":"Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials","volume":"15","author":"Lim","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0015","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.7717\/peerj.835","article-title":"Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: Systematic review and meta-analysis","volume":"3","author":"Shantha","year":"2015","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0016","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: A systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2054358118792010","article-title":"Association between low-molecular-weight heparin and risk of bleeding among hemodialysis patients: A retrospective cohort study","volume":"5","author":"Lazrak","year":"2018","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0018","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","article-title":"Renal Association Clinical Practice Guideline on haemodialysis","volume":"20","author":"Ashby","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0019","article-title":"Regional citrate anticoagulation: a tale of more than two stories","author":"Evenepoel","year":"2023","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0020","article-title":"Clotting propensity of surface-treated membranes in a hemodialysis set-up that avoids systemic Q1 Anticoagulation","author":"Franssen","year":"2023","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151483","article-title":"Avoiding systemic heparinization during hemodialysis: how the dialysis setup might help","author":"Janssens","year":"2023","journal-title":"Semin Nephrol"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151478_bib0022","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"issue":"9854","key":"10.1016\/j.semnephrol.2023.151478_bib0023","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2023.151478_bib0024","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"7329","key":"10.1016\/j.semnephrol.2023.151478_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0026","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0027","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10557-019-06882-0","article-title":"Efficacy of antiplatelet agent usage for primary and secondary prevention in dialysis patients: A nationwide data survey and propensity analysis","volume":"33","author":"Chen","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0028","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2007.07.007","article-title":"Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"50","author":"\u00c9thier","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1016\/j.semnephrol.2023.151478_bib0029","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.299.18.2164","article-title":"Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial","volume":"299","author":"Dember","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2012.08.031","article-title":"Antiplatelet therapy to prevent hemodialysis vascular access failure: Systematic review and meta-analysis","volume":"61","author":"Palmer","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0031","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/003655998750015458","article-title":"Effects of ticlopidine in AV-fistula surgery in uremia","volume":"32","author":"Gr\u00f6ntoft","year":"1998","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151478_bib0032","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/ki.1994.192","article-title":"Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study","volume":"45","author":"Sreedhara","year":"1994","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151478_bib0033","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1172\/JCI113020","article-title":"Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition","volume":"79","author":"Gaspari","year":"1987","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12882-020-01757-1","article-title":"The risk of bleeding for antiplatelet agents in haemodialysis patients: A meta-analysis","volume":"21","author":"Wang","year":"2020","journal-title":"BMC Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151478_bib0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2215\/CJN.00810209","article-title":"Antiplatelet medications in hemodialysis patients: A systematic review of bleeding rates","volume":"4","author":"Hiremath","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151478_bib0036","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/01.ASN.0000081661.10246.33","article-title":"Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis","volume":"14","author":"Kaufman","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"4 suppl 3","key":"10.1016\/j.semnephrol.2023.151478_bib0037","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","author":"Bolton","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0038","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","article-title":"KDOQI clinical practice guideline for vascular access: 2019 update","volume":"75","author":"Lok","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151478_bib0039","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/ndt\/gfaa106","article-title":"Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults","volume":"35","author":"Gallieni","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0040","series-title":"Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease","first-page":"395","article-title":"Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism","author":"Marongiu","year":"2015"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0041","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0042","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11239-006-5580-y","article-title":"Worldwide management of oral anticoagulant therapy: The ISAM study","volume":"21","author":"Pengo","year":"2006","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151478_bib0043","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: Relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151478_bib0044","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/ki.2009.477","article-title":"Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy","volume":"77","author":"Wizemann","year":"2010","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2010050459","article-title":"The increasing prevalence of atrial fibrillation among hemodialysis patients","volume":"22","author":"Winkelmayer","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0046","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","article-title":"Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis","volume":"27","author":"Zimmerman","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0047","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0048","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151478_bib0049","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ndt\/gfy387","article-title":"Performance of bleeding risk scores in dialysis patients","volume":"34","author":"Ocak","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.03.015","article-title":"A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients","volume":"123","author":"de Jong","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0051","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2215\/CJN.00250112","article-title":"Pulmonary embolism in patients with CKD and ESRD","volume":"7","author":"Kumar","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151478_bib0052","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1160\/TH11-06-0422","article-title":"Venous and arterial thrombosis in dialysis patients","volume":"106","author":"Ocak","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0053","first-page":"874","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0054","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22886","article-title":"Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.semnephrol.2023.151478_bib0055","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151478_bib0057","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cjca.2017.02.004","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: A systematic review and meta-analysis","volume":"33","author":"Harel","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0058","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2016.09.016","article-title":"Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis","volume":"184","author":"Van Der Meersch","year":"2017","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0059","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000521494","article-title":"Warfarin use, stroke, and bleeding risk among pre-existing atrial fibrillation US veterans transitioning to dialysis","volume":"146","author":"Sy","year":"2022","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/00365590310008938","article-title":"Maintaining patency of tunneled hemodialysis catheters: Efficacy of aspirin compared to warfarin","volume":"37","author":"Obialo","year":"2003","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0061","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1561-5413(07)60005-2","article-title":"Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: A prospective randomized study","volume":"9","author":"Abdul-Rahman","year":"2007","journal-title":"Hong Kong J Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0062","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.mat.0000169115.56374.9f","article-title":"Systemic anticoagulation and prevention of hemodialysis catheter malfunction","volume":"51","author":"Zellweger","year":"2005","journal-title":"ASAIO J"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151478_bib0063","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2215\/CJN.07240810","article-title":"Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: A randomized, controlled trial","volume":"6","author":"Wilkieson","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151478_bib0064","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/01.ASN.0000027356.16598.99","article-title":"Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial","volume":"13","author":"Crowther","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151478_bib0065","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/ajkd.2002.36895","article-title":"Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"40","author":"Saran","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151478_bib0066","article-title":"Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts","volume":"2015","author":"Tanner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151478_bib0067","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0068","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9973","article-title":"Time trends in patient characteristics, anticoagulation treatment, and prognosis of incident nonvalvular atrial fibrillation in the Netherlands","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151478_bib0069","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jfma.2021.12.012","article-title":"Trends of medication used in patients with pre-ESKD from 2010 to 2018 in Taiwan","volume":"121","author":"Lin","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151478_bib0070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0071","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151478_bib0072","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151478_bib0073","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151478_bib0074","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151478_bib0075","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: A multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151478_bib0076","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0077","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151478_bib0078","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/STROKEAHA.120.028934","article-title":"Direct-acting oral anticoagulants versus warfarin in Medicare patients with chronic kidney disease and atrial fibrillation","volume":"51","author":"Wetmore","year":"2020","journal-title":"Stroke"},{"issue":"15","key":"10.1016\/j.semnephrol.2023.151478_bib0079","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151478_bib0081","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.semnephrol.2023.151478_bib0082","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151478_bib0083","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151478_bib0084","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"26","key":"10.1016\/j.semnephrol.2023.151478_bib0085","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151478_bib0086","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151478_bib0087","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0088","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J Hosp Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151478_bib0089","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.14021021","article-title":"Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis","volume":"17","author":"Wetmore","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151478_bib0090","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0091","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151478_bib0092","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151478_bib0093","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0094","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151478_bib0095","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","article-title":"Anticoagulation management in haemodialysis patients with atrial fibrillation: Evidence and opinion","volume":"37","author":"De Vriese","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151478_bib0096","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151478_bib0097","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.semnephrol.2023.151478_bib0098","unstructured":"National Institute for Health and Care Excellence (NICE) guideline. Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing. 2020. Available at: https:\/\/www.nice.org.uk\/guidance\/ng158."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151478_bib0099","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151478_bib0100","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151478_bib0101","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:50:52Z","timestamp":1748357452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0270929523001882"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151478","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding Risk in Hemodialysis Patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151478"}}